244 related articles for article (PubMed ID: 30366617)
41. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
Zhang J; Liu X; Sa N; Zhang JH; Cai YS; Wang KM; Xu W; Jiang CS; Zhu KK
Eur J Med Chem; 2024 Apr; 269():116341. PubMed ID: 38518523
[TBL] [Abstract][Full Text] [Related]
43. Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1.
Ran T; Li W; Peng B; Xie B; Lu T; Lu S; Liu W
J Chem Inf Model; 2019 Jan; 59(1):522-534. PubMed ID: 30607947
[TBL] [Abstract][Full Text] [Related]
44. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors.
Chen Y; Shi Q; Yang H; Li J; Zhou K; Zhang J; Wang Z; Shi H; Xiong B; Liu J; Huang X; Liu T
Bioorg Chem; 2023 Jan; 130():106228. PubMed ID: 36356371
[TBL] [Abstract][Full Text] [Related]
46. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
[TBL] [Abstract][Full Text] [Related]
47. Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L
Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274
[TBL] [Abstract][Full Text] [Related]
48. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
[No Abstract] [Full Text] [Related]
49. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.
Shen Y; Szewczyk MM; Eram MS; Smil D; Kaniskan HÜ; de Freitas RF; Senisterra G; Li F; Schapira M; Brown PJ; Arrowsmith CH; Barsyte-Lovejoy D; Liu J; Vedadi M; Jin J
J Med Chem; 2016 Oct; 59(19):9124-9139. PubMed ID: 27584694
[TBL] [Abstract][Full Text] [Related]
50. A patent review of arginine methyltransferase inhibitors (2010-2018).
Li X; Wang C; Jiang H; Luo C
Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
[TBL] [Abstract][Full Text] [Related]
51. In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking.
Luo L; Tan H; Liao Y
J Biomol Struct Dyn; 2023; 41(22):13180-13197. PubMed ID: 36856049
[TBL] [Abstract][Full Text] [Related]
52. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
53. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
54. Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*.
Sutherland M; Li A; Kaghad A; Panagopoulos D; Li F; Szewczyk M; Smil D; Scholten C; Bouché L; Stellfeld T; Arrowsmith CH; Barsyte D; Vedadi M; Hartung IV; Steuber H; Britton R; Santhakumar V
ChemMedChem; 2021 Apr; 16(7):1116-1125. PubMed ID: 33513288
[TBL] [Abstract][Full Text] [Related]
55. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer.
Liu S; Liu Z; Piao C; Zhang Z; Kong C; Yin L; Liu X
J Exp Clin Cancer Res; 2022 Oct; 41(1):293. PubMed ID: 36199122
[TBL] [Abstract][Full Text] [Related]
56. Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors.
Yu XR; Tang Y; Wang WJ; Ji S; Ma S; Zhong L; Zhang CH; Yang J; Wu XA; Fu ZY; Li LL; Yang SY
Bioorg Med Chem Lett; 2015 Nov; 25(22):5449-53. PubMed ID: 26428871
[TBL] [Abstract][Full Text] [Related]
57. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
Zhou Z; Feng Z; Hu D; Yang P; Gur M; Bahar I; Cristofanilli M; Gradishar WJ; Xie XQ; Wan Y
EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
[TBL] [Abstract][Full Text] [Related]
58. Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.
Wan H; Huynh T; Pang S; Geng J; Vaccaro W; Poss MA; Trainor GL; Lorenzi MV; Gottardis M; Jayaraman L; Purandare AV
Bioorg Med Chem Lett; 2009 Sep; 19(17):5063-6. PubMed ID: 19632837
[TBL] [Abstract][Full Text] [Related]
59. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with
Cottrell KM; Briggs KJ; Whittington DA; Jahic H; Ali JA; Davis CB; Gong S; Gotur D; Gu L; McCarren P; Tonini MR; Tsai A; Wilker EW; Yuan H; Zhang M; Zhang W; Huang A; Maxwell JP
J Med Chem; 2024 Apr; 67(8):6064-6080. PubMed ID: 38595098
[TBL] [Abstract][Full Text] [Related]
60. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Jensen-Pergakes K; Tatlock J; Maegley KA; McAlpine IJ; McTigue M; Xie T; Dillon CP; Wang Y; Yamazaki S; Spiegel N; Shi M; Nemeth A; Miller N; Hendrickson E; Lam H; Sherrill J; Chung CY; McMillan EA; Bryant SK; Palde P; Braganza J; Brooun A; Deng YL; Goshtasbi V; Kephart SE; Kumpf RA; Liu W; Patman RL; Rui E; Scales S; Tran-Dube M; Wang F; Wythes M; Paul TA
Mol Cancer Ther; 2022 Jan; 21(1):3-15. PubMed ID: 34737197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
